{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:37:09Z","timestamp":1789040229286,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["U44AI167783"],"award-info":[{"award-number":["U44AI167783"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05299-5","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:07:15Z","timestamp":1742224035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection"],"prefix":"10.1186","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct05604521","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrea A.","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. W. Preston","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhaunshu","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abra Rachida","family":"Koudjra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauryn","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Lyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"5299_CR1","unstructured":"WHO. World Malaria Report 2023: tracking progress and gaps in the global response to malaria. Geneva: World Health Organization; 2023."},{"key":"5299_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14760584.2023.2292204","volume":"23","author":"EA Hammershaimb","year":"2024","unstructured":"Hammershaimb EA, Berry AA. Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond. Expert Rev Vaccines. 2024;23:49\u201352.","journal-title":"Expert Rev Vaccines"},{"key":"5299_CR3","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","volume":"403","author":"KP Asante","year":"2024","unstructured":"Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, et al. Feasibility, safety, and impact of the RTS,S\/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet. 2024;403:1660\u201370.","journal-title":"Lancet"},{"key":"5299_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006465","volume":"4","author":"ME Polhemus","year":"2009","unstructured":"Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, et al. Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area. PLoS ONE. 2009;4: e6465.","journal-title":"PLoS ONE"},{"key":"5299_CR5","unstructured":"WHO. Malaria vaccines: preferred product characteristics and clinical development considerations. Geneva, World Health Organization; 2022."},{"key":"5299_CR6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","volume":"22","author":"TL Richie","year":"2023","unstructured":"Richie TL, Church LWP, Murshedkar T, Billingsley PF, James ER, Chen MC, et al. Sporozoite immunization: innovative translational science to support the fight against malaria. Expert Rev Vaccines. 2023;22:964\u20131007.","journal-title":"Expert Rev Vaccines"},{"key":"5299_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"5299_CR8","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson Ii PA, et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin Infect Dis. 2020;71:2849\u201357.","journal-title":"Clin Infect Dis"},{"key":"5299_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"5299_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2022","unstructured":"Sissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis. 2022;22:377\u201389.","journal-title":"Lancet Infect Dis"},{"key":"5299_CR11","doi-asserted-by":"crossref","unstructured":"Sirima SB, Ouedraogo A, Tiono AB, Kabore JM, Bougouma EC, Ouattara MS, et al. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria. Sci Transl Med. 2022;14:eabj3776.","DOI":"10.1126\/scitranslmed.abj3776"},{"key":"5299_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S1473-3099(24)00360-8","volume":"24","author":"H Diawara","year":"2024","unstructured":"Diawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, et al. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2024;24:1366\u201382.","journal-title":"Lancet Infect Dis"},{"key":"5299_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s44321-024-00057-7","volume":"16","author":"D Goswami","year":"2024","unstructured":"Goswami D, Patel H, Betz W, Armstrong J, Camargo N, Patil A, et al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol Med. 2024;16:723\u201354.","journal-title":"EMBO Mol Med"},{"key":"5299_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalage SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, Immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99:338\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"5299_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg. 2018;98:308\u201318.","journal-title":"Am J Trop Med Hyg"},{"key":"5299_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and differential antibody and t-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ Vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019;100:1433\u201344.","journal-title":"Am J Trop Med Hyg"},{"key":"5299_CR17","doi-asserted-by":"crossref","unstructured":"Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020;12:eaaz5629.","DOI":"10.1126\/scitranslmed.aaz5629"},{"key":"5299_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciz925","volume":"71","author":"LC Steinhardt","year":"2020","unstructured":"Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. 2020;71:1063\u201371.","journal-title":"Clin Infect Dis"},{"key":"5299_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021;27:1636\u201345.","journal-title":"Nat Med"},{"key":"5299_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","volume":"104","author":"SA Jongo","year":"2021","unstructured":"Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in Equatoguinean adults. Am J Trop Med Hyg. 2021;104:283\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"5299_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.21-0942","volume":"106","author":"SA Jongo","year":"2022","unstructured":"Jongo SA, Church LWP, Nchama V, Hamad A, Chuquiyauri R, Kassim KR, et al. Multi-dose priming regimens of PfSPZ Vaccine: safety and efficacy against controlled human malaria infection in Equatoguinean adults. Am J Trop Med Hyg. 2022;106:1215\u201326.","journal-title":"Am J Trop Med Hyg"},{"key":"5299_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-022-00510-z","volume":"7","author":"B Mordmuller","year":"2022","unstructured":"Mordm\u00fcller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, et al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022;7:100.","journal-title":"NPJ Vaccines"},{"key":"5299_CR23","doi-asserted-by":"crossref","unstructured":"Jongo SA, Urbano Nsue Ndong Nchama V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Safety and immunogenicity of radiation-attenuated PfSPZ Vaccine in Equatoguinean Infants, children, and adults. Am J Trop Med Hyg. 2023;109:138\u201346.","DOI":"10.4269\/ajtmh.22-0773"},{"key":"5299_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.chom.2008.08.010","volume":"4","author":"AM Vaughan","year":"2008","unstructured":"Vaughan AM, Aly AS, Kappe SH. Malaria parasite pre-erythrocytic stage infection: gliding and hiding. Cell Host Microbe. 2008;4:209\u201318.","journal-title":"Cell Host Microbe"},{"key":"5299_CR25","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, et al. Multidose priming and delayed boosting improve Plasmodium falciparum sporozoite vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin Infect Dis. 2021;73:e2424\u201335.","journal-title":"Clin Infect Dis"},{"key":"5299_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017;2: e89154.","journal-title":"JCI Insight"},{"key":"5299_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(08)60418-3","volume":"371","author":"TA Gaziano","year":"2008","unstructured":"Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923\u201331.","journal-title":"Lancet"},{"key":"5299_CR28","first-page":"1981","volume":"123","author":"BJ Delemarre","year":"1979","unstructured":"Delemarre BJ, van der Kaay HJ. [Tropical malaria contracted the natural way in the Netherlands](in Dutch). Ned Tijdschr Geneeskd. 1979;123:1981\u20132.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"5299_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0035-9203(84)90114-7","volume":"78","author":"TR Burkot","year":"1984","unstructured":"Burkot TR, Williams JL, Schneider I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg. 1984;78:339\u201341.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5299_CR30","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41467-022-30882-8","volume":"13","author":"JC Silva","year":"2022","unstructured":"Silva JC, Dwivedi A, Moser KA, Sissoko MS, Epstein JE, Healy SA, et al. Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nat Commun. 2022;13:3390.","journal-title":"Nat Commun"},{"key":"5299_CR31","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","volume":"220","author":"MB Laurens","year":"2019","unstructured":"Laurens MB, Berry AA, Travassos MA, Strauss K, Adams M, Shrestha B, et al. Dose-dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J Infect Dis. 2019;220:1962\u20136.","journal-title":"J Infect Dis"},{"key":"5299_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595:289\u201394.","journal-title":"Nature"},{"key":"5299_CR33","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok Z, Fendel R, Eder B, Lorenz FR, KC N, Karnahl M, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12:2518.","journal-title":"Nat Commun"},{"key":"5299_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"5299_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(87)90480-6","volume":"1","author":"MM Levine","year":"1987","unstructured":"Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1:1049\u201352.","journal-title":"Lancet"},{"key":"5299_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614\u201323.","journal-title":"Nat Med"},{"key":"5299_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031247","volume":"7","author":"WR Weiss","year":"2012","unstructured":"Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS ONE. 2012;7: e31247.","journal-title":"PLoS ONE"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05299-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:07:22Z","timestamp":1742224042000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05299-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5299"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05299-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical protocol was reviewed and approved by the WCG investigational review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"T.L.R., L.W.P.C., N.K.C., M.C.C., Y.A., T.M., E.R.J. P.F.B., B.K.L.S., and S.L.H  were salaried, full-time employees of Sanaria Inc at the time of this study. B.K.L.S. and S.L.H. own stock in Sanaria.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}